43 results on '"Mai, Elias K"'
Search Results
2. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
- Author
-
Mai, Elias K, Goldschmidt, Hartmut, Miah, Kaya, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Krzykalla, Julia, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor W, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Kunz, Christina, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M, Kunz, Christian, Hensel, Manfred, Benner, Axel, Seidel-Glätzer, Andrea, Weisel, Katja C, Raab, Marc S, Salwender, Hans J, Adrian, Nicole, Bernhard, Helga, Böck, Hans-Peter, Bolling, Claus, Dingeldein, Gerrit, Emde, Till-Oliver, Ferstl, Barbara, Fietz, Thomas, Fronhoffs, Stefan, Fuhrmann, Stephan, Fuxius, Stefan, Geer, Thomas, Görner, Martin, Guenther, Barbara, Hartmann, Frank, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Klein, Stefan, Klump, Martin, Knauf, Wolfgang, La Rosée, Paul, Lange, Elisabeth, Lindemann, Walter, Lopez, Roderico, Mayer, Frank, Nückel, Holger, Papesch, Eva, Procaccianti, Maria, Reichart, Alexander, Rummel, Mathias, Scheuer, Lars, Schmitt, Hans-Roland, Staib, Peter, Steiniger, Heike, Tischler, Hans-Joachim, Ulshöfer, Thomas, Verbeek, Walter, Wacker, Alexander, and Zirpel, Iris
- Abstract
The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma.
- Published
- 2024
- Full Text
- View/download PDF
3. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Bertsch, Uta, Fenk, Roland, Nievergall, Eva, Tichy, Diana, Besemer, Britta, Dürig, Jan, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Asemissen, Anne M, Heilmeier, Bernhard, Weinhold, Niels, Huhn, Stefanie, Kriegsmann, Katharina, Luntz, Steffen P, Holderried, Tobias A W, Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Müller, Martin, Khandanpour, Cyrus, Knauf, Wolfgang, Scheid, Christof, Munder, Markus, Geer, Thomas, Riesenberg, Hendrik, Thomalla, Jörg, Hoffmann, Martin, Raab, Marc S, Salwender, Hans J, Weisel, Katja C, Asemissen, Anne M, Behringer, Joachim, Bernhard, Helga, Bernhardt, Christiane, Bertsch, Uta, Besemer, Britta, Blau, Igor W, Bolling, Claus, Debatin, Daniel, Dingeldein, Gerrit, Dürig, Jan, Fenk, Roland, Ferstl, Barbara, Fest, Claudia, Fronhoffs, Stefan, Fuhrmann, Stephan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Grassinger, Jochen, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Held, Gerhard, Hoffmann, Martin, Holderried, Tobias A W, Hopfer, Olaf, Huhn, Stefanie, Immenschuh, Peter, Kaddu-Mulindwa, Dominic, Khandanpour, Cyrus, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Köchling, Georg, Koenigsmann, Michael, Kostrewa, Philippe, Kraemer, Doris Maria, Kremers, Stephan, Kriegsmann, Katharina, Kropff, Martin, La Rosée, Paul, Luntz, Steffen P, Mahlberg, Rolf, Mai, Elias K, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Müller, Martin, Munder, Markus, Neise, Michael, Nievergall, Eva, Nückel, Holger, Pönisch, Wolfram, Procaccianti, Maria, Raab, Marc S, Rafiyan, Mohammed R, Reimer, Peter, Riecke, Armin, Riesenberg, Hendrik, Rummel, Mathias, Runde, Volker, Salwender, Hans J, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schmitt, Stefan, Schöndube, Daniel, Schroers, Roland, Schwarzer, Andreas, Staib, Peter, Steiniger, Heike, Sturmberg, Dirk, Thomalla, Jörg, Tichy, Diana, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Trummer, Arne, Tschechne, Barbara, Verbeek, Walter, Weinhold, Niels, Weisel, Katja C, Whitlock, Bettina, de Wit, Maike, Zaiß, Matthias, and Ziske, Carsten
- Abstract
Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed transplantation-eligible multiple myeloma.
- Published
- 2022
- Full Text
- View/download PDF
4. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
- Author
-
Kriegsmann, Katharina, Manta, Calin, Schwab, Ricarda, Mai, Elias K., Raab, Marc S., Salwender, Hans J., Fenk, Roland, Besemer, Britta, Dürig, Jan, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Asemissen, Anne M., Heilmeier, Bernhard, Bertsch, Uta, Huhn, Stefanie, Müller-Tidow, Carsten, Goldschmidt, Hartmut, and Hundemer, Michael
- Published
- 2023
- Full Text
- View/download PDF
5. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
- Author
-
Kriegsmann, Katharina, Manta, Calin, Schwab, Ricarda, Mai, Elias K., Raab, Marc S., Salwender, Hans J., Fenk, Roland, Besemer, Britta, Dürig, Jan, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Asemissen, Anne M., Heilmeier, Bernhard, Bertsch, Uta, Huhn, Stefanie, Müller-Tidow, Carsten, Goldschmidt, Hartmut, and Hundemer, Michael
- Published
- 2023
- Full Text
- View/download PDF
6. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
- Author
-
Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut
- Abstract
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n= 1333) and three validation cohorts (n= 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p< 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.
- Published
- 2023
- Full Text
- View/download PDF
7. Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
- Author
-
Mai, Elias K, Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M, Scheid, Christof, Weisel, Katja, Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor Wolfgang, Haenel, Mathias, Salwender, Hans, Benner, Axel, Raab, Marc S, Goldschmidt, Hartmut, and Weinhold, Niels
- Published
- 2022
- Full Text
- View/download PDF
8. Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients
- Author
-
Kaiser, Martin F., Sonneveld, Pieter, Cairns, David, Raab, Marc S, Larocca, Alessandra, Brown, Sarah R, Baertsch, Marc-A., Li, Cong, Musto, Pellegrino, Yong, Kwee, Mai, Elias K, Capra, Andrea, Cook, Gordon, Goldschmidt, Hartmut, Boccadoro, Mario, Jackson, Graham, Weinhold, Niels, and Gay, Francesca
- Published
- 2022
- Full Text
- View/download PDF
9. Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
- Author
-
Steiger, Simon, Lutz, Raphael, Prokoph, Nina, Palit, Subarna, Tirier, Stephan M, Reichert, Philipp, Baumann, Anja, Hefner, Nadine, Schumacher, Sabrina, Vonficht, Dominik, Grünschläger, Florian, Poos, Alexandra M, John, Lukas, Haghverdi, Laleh, Mallm, Jan-Philipp, Mai, Elias K, Friedrich, Mirco, Kriegsmann, Katharina, Awwad, Mohamed H.S., Jauch, Anna, Bertsch, Uta, Tichy, Diana, Müller-Tidow, Carsten, Schroers, Roland, Salwender, Hans, Besemer, Britta, Fenk, Roland, Weisel, Katja, Goldschmidt, Hartmut, Huhn, Stefanie, Hundemer, Michael, Rippe, Karsten, Haas, Simon, Weinhold, Niels, and Raab, Marc S
- Published
- 2022
- Full Text
- View/download PDF
10. Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients
- Author
-
Kaiser, Martin F., Sonneveld, Pieter, Cairns, David, Raab, Marc S, Larocca, Alessandra, Brown, Sarah R, Baertsch, Marc-A., Li, Cong, Musto, Pellegrino, Yong, Kwee, Mai, Elias K, Capra, Andrea, Cook, Gordon, Goldschmidt, Hartmut, Boccadoro, Mario, Jackson, Graham, Weinhold, Niels, and Gay, Francesca
- Published
- 2022
- Full Text
- View/download PDF
11. Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
- Author
-
Steiger, Simon, Lutz, Raphael, Prokoph, Nina, Palit, Subarna, Tirier, Stephan M, Reichert, Philipp, Baumann, Anja, Hefner, Nadine, Schumacher, Sabrina, Vonficht, Dominik, Grünschläger, Florian, Poos, Alexandra M, John, Lukas, Haghverdi, Laleh, Mallm, Jan-Philipp, Mai, Elias K, Friedrich, Mirco, Kriegsmann, Katharina, Awwad, Mohamed H.S., Jauch, Anna, Bertsch, Uta, Tichy, Diana, Müller-Tidow, Carsten, Schroers, Roland, Salwender, Hans, Besemer, Britta, Fenk, Roland, Weisel, Katja, Goldschmidt, Hartmut, Huhn, Stefanie, Hundemer, Michael, Rippe, Karsten, Haas, Simon, Weinhold, Niels, and Raab, Marc S
- Published
- 2022
- Full Text
- View/download PDF
12. Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
- Author
-
Mai, Elias K, Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M, Scheid, Christof, Weisel, Katja, Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor Wolfgang, Haenel, Mathias, Salwender, Hans, Benner, Axel, Raab, Marc S, Goldschmidt, Hartmut, and Weinhold, Niels
- Published
- 2022
- Full Text
- View/download PDF
13. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
- Author
-
Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan, and Goldschmidt, Hartmut
- Published
- 2021
- Full Text
- View/download PDF
14. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
- Author
-
Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., and Goldschmidt, Hartmut
- Abstract
Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n= 353), 61–65 years (S2, n= 107) and 66–70 years (S3, n= 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p= 0.05/<0.001). With respect to progression-free survival (log-rank p= 0.73), overall survival (log-rank p= 0.54) as well as time-to-progression (Gray’s p= 0.83) and non-relapse mortality (Gray’s p= 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.
- Published
- 2021
- Full Text
- View/download PDF
15. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K., Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Hügle-Dörr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Hänel, Mathias, and Salwender, Hans J.
- Abstract
The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n= 502): arms A1:PAd + LEN-2Y (n= 125), B1:PAd + LEN-CR (n= 126), A2:VCD + LEN-2Y (n= 126), B2:VCD + LEN-CR (n= 125). In the LEN-CR group (B1 + B2), n= 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p= 0.60, primary endpoint) nor overall survival (OS) (p= 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p= 0.03) but not PFS (HR = 1.15, p= 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p= 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p= 0.01). LEN MT should be applied beyond CR for at least 2 years.
- Published
- 2020
- Full Text
- View/download PDF
16. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma
- Author
-
Merz, Maximilian, Hielscher, Thomas, Schult, David, Mai, Elias K., Raab, Marc S., Hillengass, Jens, Seckinger, Anja, Hose, Dirk, Granzow, Martin, Jauch, Anna, and Goldschmidt, Hartmut
- Published
- 2020
- Full Text
- View/download PDF
17. Continued need for autologous transplantation in relapsed myeloma
- Author
-
Mai, Elias K
- Published
- 2024
- Full Text
- View/download PDF
18. Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
- Author
-
Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., and Goldschmidt, Hartmut
- Published
- 2024
- Full Text
- View/download PDF
19. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
- Author
-
Cirrincione, Anthony M., Poos, Alexandra M., Ziccheddu, Bachisio, Kaddoura, Marcella, Bärtsch, Marc-Andrea, Maclachlan, Kylee, Chojnacka, Monika, Diamond, Benjamin, John, Lukas, Reichert, Philipp, Huhn, Stefanie, Blaney, Patrick, Gagler, Dylan, Rippe, Karsten, Zhang, Yanming, Dogan, Ahmet, Lesokhin, Alexander M., Davies, Faith, Goldschmidt, Hartmut, Fenk, Roland, Weisel, Katja C., Mai, Elias K., Korde, Neha, Morgan, Gareth J., Usmani, Saad, Landgren, Ola, Raab, Marc S., Weinhold, Niels, and Maura, Francesco
- Abstract
•HY, historically considered an initiating event in MM, can be preceded by deletions involving driver genes.•Deletions within large chromosomal gains represent a novel mechanism that impacts both driver gene expression and clinical outcomes.
- Published
- 2024
- Full Text
- View/download PDF
20. Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial
- Author
-
Ton, Gigi Nu Hoang Quy, Kriegsmann, Katharina, Awwad, Mohamed H.S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor Wolfgang, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Neubauer, Andreas, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe, Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja, Salwender, Hans, Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael
- Abstract
Introduction: Elotuzumab, a monoclonal antibody targeting SLAM family member 7 protein (SLAMF7) on multiple myeloma (MM) cells, has shown promise in relapsed/refractory MM when combined with immunomodulatory agents. However, its effectiveness in newly diagnosed patients did not show improved progression-free survival (PFS) nor overall survival. In a previous study we demonstrated that elotuzumab specifically depleted high SLAMF7 expressing regulatory CD8 +T cells by macrophage induced antibody dependent phagocytosis. This study aimed to identify immunological predictive factors for elotuzumab efficacy, enabling improved risk stratification and personalized treatment decisions based on the detection and quantification of SLAMF7-positive T cell subsets.
- Published
- 2023
- Full Text
- View/download PDF
21. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse
- Author
-
Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias K., Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Hänel, Mathias, von Metzler, Ivana, Hans W., Lindemann, Scheid, Christof, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, Weisel, Katja, and Goldschmidt, Hartmut
- Abstract
IntroductionThe randomized, controlled, multicenter, phase III GMMG ReLApsE trial compared lenalidomide/dexamethasone (Rd) re-induction, salvage high dose chemotherapy, autologous stem cell transplantation (HDCT/ASCT) and lenalidomide (R) maintenance with standard continuous Rd. We have previously reported the absence of a significant survival benefit in the primary analysis. However, landmark analyses from salvage HDCT performed due to the fact that ~30% of patients in the HDCT arm did not receive salvage HDCT/ASCT suggested a survival benefit in patients undergoing salvage HDCT/ASCT. Here we report long term follow up results from the GMMG ReLApsE trial.
- Published
- 2023
- Full Text
- View/download PDF
22. Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma
- Author
-
Cirrincione, Anthony, Kaddoura, Marcella, Poos, Alexandra Maria, Ziccheddu, Bachisio, Maclachlan, Kylee H, Chojnacka, Monika, Diamond, Benjamin, Blaney, Patrick, Gagler, Dylan, Zhang, Yanming, Dogan, Ahmet, Lesokhin, Alexander, Davies, Faith E., Goldschmidt, Hartmut, Weisel, Katja, Fenk, Roland, Mai, Elias K., Korde, Neha, Morgan, Gareth J., Raab, Marc S., Usmani, Saad Z, Landgren, Ola, Weinhold, Niels, and Maura, Francesco
- Abstract
INTRODUCTION: Multiple myeloma (MM) evolution is complex and heterogeneous. Hyperdiploidy (HRD) and translocations affecting the immunoglobulin heavy chain (IGH) locus are historically considered initiating genomic events of MM. The potential impact of genomic events acquired before known MM initiating events has never been addressed.
- Published
- 2023
- Full Text
- View/download PDF
23. The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma
- Author
-
Maura, Francesco, Kaddoura, Marcella, Poos, Alexandra Maria, Cirrincione, Anthony, Diamond, Benjamin, Maclachlan, Kylee H, Ziccheddu, Bachisio, Mai, Elias K., Goldschmidt, Hartmut, Weisel, Katja, Fenk, Roland, Morgan, Gareth J., Usmani, Saad Z, Landgren, Ola, Raab, Marc S., and Weinhold, Niels
- Abstract
INTRODUCTION:Multiple myeloma (MM) evolution is shaped by the acquisition and selection of distinct genomic events over time. While various temporal patterns have been identified, the precise chronological order in which key clonal genomic defining events are acquired, and their specific impact on clinical outcomes remain to be fully elucidated.
- Published
- 2023
- Full Text
- View/download PDF
24. Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation
- Author
-
Blaney, Patrick, Walker, Brian A., Mikulasova, Aneta, Gagler, Dylan, Ziccheddu, Bachisio, Diamond, Benjamin, Wang, Yubao, Hou, Liming, Liu, Sanxiong, Poos, Alexandra Maria, Cirrincione, Anthony, Maclachlan, Kylee H, Mai, Elias K., Goldschmidt, Hartmut, Usmani, Saad Z, Raab, Marc S., Weinhold, Niels, Landgren, Ola, Davies, Faith E., Maura, Francesco, and Morgan, Gareth J.
- Abstract
INTRODUCTION:Little is known about the pattern and function of mutations within the 98% of the genome which is non-coding (nc). Whole-genome sequencing (WGS) can identify the full range of single nucleotide variants (SNVs), insertions/deletions (InDels), copy-number variants (CNVs), and structural variants (SVs), which are critical to disease progression. Here, we characterize the non-coding genome to gain significant insight into the role of mutations in gene regulatory elements in the etiology of multiple myeloma (MM) and to models of how it develops.
- Published
- 2023
- Full Text
- View/download PDF
25. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- Author
-
Kortüm, K. Martin, Mai, Elias K., Hanafiah, Nur H., Shi, Chang-Xi, Zhu, Yuan-Xiao, Bruins, Laura, Barrio, Santiago, Jedlowski, Patrick, Merz, Maximilian, Xu, Jing, Stewart, Robert A., Andrulis, Mindaugas, Jauch, Anna, Hillengass, Jens, Goldschmidt, Hartmut, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith, and Raab, Marc S.
- Abstract
In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation Panel. Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), and 88%, 78%, and 68% were refractory to an IMiD, a PI, or both, respectively. The majority of patients had progressive (82%) or refractory (78%) disease immediately before sampling, with 43% being IMiD refractory and 46% being PI refractory in the most recent line of therapy. Compared with newly diagnosed MM, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed. Longitudinal analyses performed in 3 patients with CRBN mutations at time of IMiD resistance confirmed that these mutations were undetectable at earlier, IMiD-sensitive time points. Furthermore, the functional introduction of these mutations in MM cells conferred lenalidomide resistance in vitro. These data indicate a differential genetic landscape in rMM associated with drug response.
- Published
- 2016
- Full Text
- View/download PDF
26. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBNand Ras pathway genes
- Author
-
Kortüm, K.Martin, Mai, Elias K., Hanafiah, Nur H., Shi, Chang-Xi, Zhu, Yuan-Xiao, Bruins, Laura, Barrio, Santiago, Jedlowski, Patrick, Merz, Maximilian, Xu, Jing, Stewart, Robert A., Andrulis, Mindaugas, Jauch, Anna, Hillengass, Jens, Goldschmidt, Hartmut, Bergsagel, P.Leif, Braggio, Esteban, Stewart, A.Keith, and Raab, Marc S.
- Abstract
In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation Panel. Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), and 88%, 78%, and 68% were refractory to an IMiD, a PI, or both, respectively. The majority of patients had progressive (82%) or refractory (78%) disease immediately before sampling, with 43% being IMiD refractory and 46% being PI refractory in the most recent line of therapy. Compared with newly diagnosed MM, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF(72%), as well as TP53(26%), CRBN(12%), and CRBN pathway genes (10%) was observed. Longitudinal analyses performed in 3 patients with CRBNmutations at time of IMiD resistance confirmed that these mutations were undetectable at earlier, IMiD-sensitive time points. Furthermore, the functional introduction of these mutations in MM cells conferred lenalidomide resistance in vitro. These data indicate a differential genetic landscape in rMM associated with drug response.
- Published
- 2016
- Full Text
- View/download PDF
27. 18F-FDG Dynamic PETCT in Patients with Multiple Myeloma
- Author
-
Sachpekidis, Christos, Mai, Elias K., Goldschmidt, Hartmut, Hillengass, Jens, Hose, Dirk, Pan, Leyun, Haberkorn, Uwe, and Dimitrakopoulou-Strauss, Antonia
- Abstract
The value of 18F-FDG PET in the diagnostic approach of multiple myeloma (MM) remains incompletely elicited. Little is known about the kinetics of 18F-FDG in the bone marrow and extramedullary sites in MM. This study aimed to evaluate quantitative data on kinetics and distribution patterns of 18F-FDG in MM patients with regard to pelvic bone marrow plasma cell infiltration.
- Published
- 2015
- Full Text
- View/download PDF
28. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Nievergall, Eva, Fenk, Roland, Bertsch, Uta, Tichy, Diana, Besemer, Britta, Dürig, Jan, Schroers, Roland, Metzler, Ivana v., Haenel, Mathias, Mann, Christoph, Asemissen, Anne-Marie, Heilmeier, Bernhard, Huhn, Stefanie, Kriegsmann, Katharina, Weinhold, Niels, Luntz, Steffen P., Holderried, Tobias A.W., Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Mueller, Martin, Khandanpour, Cyrus, Knauf, Wolfgang, Munder, Markus, Geer, Thomas, Riesenberg, Hendrik, Thomalla, Joerg, Hoffmann, Martin, Raab, Marc-Steffen, Salwender, Hans, and Weisel, Katja
- Abstract
Background:In newly-diagnosed multiple myeloma (NDMM), lenalidomide/bortezomib/dexamethasone (RVd) is one of the most widely used combination regimens. Anti-CD38 monoclonal antibodies (CD38-moAb) increase efficacy when added to standard-of-care regimens. Here we present the first primary endpoint of the randomized, open-label, multicenter, phase III GMMG-HD7 trial, comparing RVd without (arm IA) or with the CD38-moAb isatuximab (Isa, arm IB) with regard to the rate of minimal residual disease (MRD) negativity after induction therapy in patients with transplant-eligible NDMM.
- Published
- 2021
- Full Text
- View/download PDF
29. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Bertsch, Uta, Besemer, Britta, Haenel, Mathias, Miah, Kaya, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor Wolfgang, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Kunz, Christina, Neubauer, Andreas, Scheid, Christof, Schroers, Roland, Metzler, Ivana v., Schieferdecker, Aneta, Thomalla, Joerg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glaetzer, Andrea, Weisel, Katja, Raab, Marc-Steffen, and Salwender, Hans
- Abstract
Background:Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM.
- Published
- 2021
- Full Text
- View/download PDF
30. Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network
- Author
-
Mai, Elias K, Hielscher, Thomas, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Munder, Markus, Pantani, Lucia, Brossart, Peter, Beksac, Meral, Blau, Igor Wolfgang, Raab, Marc-Steffen, Dürig, Jan, Giesen, Nicola, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Haenel, Mathias, Metzler, Ivana v., Graeven, Ullrich, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Weisel, Katja, Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut
- Abstract
Background:During the past decade, prognostic tools and outcomes of patients with newly-diagnosed multiple myeloma (NDMM) markedly improved. Data from clinical trials evaluating early morbidity and mortality including patients with transplant-eligible NDMM treated with novel agents are scarce. Thus, we aimed to analyze early morbidity and mortality in this patient cohort, devise and validate a predictive score to identify patients at risk.
- Published
- 2021
- Full Text
- View/download PDF
31. Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network
- Author
-
Mai, Elias K, Hielscher, Thomas, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Munder, Markus, Pantani, Lucia, Brossart, Peter, Beksac, Meral, Blau, Igor Wolfgang, Raab, Marc-Steffen, Dürig, Jan, Giesen, Nicola, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Haenel, Mathias, Metzler, Ivana v., Graeven, Ullrich, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Weisel, Katja, Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut
- Abstract
Mai: Celgene / BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Glaxo Smith Kline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding. Salwender: AbbVie: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Amgen: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Takeda: Honoraria; Sanofi: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; GlaxoSmithKline: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Janssen-Cilag: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Bristol-Myers Squibb/Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Oncopeptides: Honoraria; Chugai: Honoraria; Pfizer: Honoraria. Zweegman: Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Munder: GSK: Consultancy; BMS: Consultancy, Honoraria; Abbvie: Consultancy; Takeda: Consultancy, Honoraria; Amgen: Honoraria; Sanofi: Consultancy; Janssen: Consultancy, Honoraria; Incyte: Research Funding. Pantani: Janssen: Honoraria; Amgen: Honoraria. Brossart: BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; MSD: Honoraria. Beksac: Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Sanofi: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Oncopeptides: Consultancy. Raab: BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy; Abbvie: Consultancy, Honoraria; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Dürig: Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Besemer: Takeda: Honoraria; Janssen: Honoraria; GSK: Honoraria. Fenk: GSK: Honoraria; Amgen: Honoraria; Janssen: Honoraria; BMS/Celgene: Honoraria; Takeda: Honoraria. Haenel: Bayer Vital: Honoraria; Jazz: Consultancy, Honoraria; GSK: Consultancy; Takeda: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy; Celgene: Consultancy, Honoraria. Metzler: Takeda: Consultancy; BMS: Consultancy; GSK: Consultancy; Amgen: Consultancy; Janssen: Consultancy; AstraZeneca: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy. Graeven: Amgen: Honoraria; Sanofi Aventis: Honoraria; Celgene: Honoraria, Research Funding; Johnson and Johnson: Honoraria; Astra Zeneca: Honoraria; MSD: Consultancy; Boehringer Ingelheim: Honoraria; BMS: Honoraria; Fujifilm: Honoraria; Roche: Research Funding; Gilead: Research Funding; Ipsen Bioscience: Research Funding; MacroGenics: Research Funding. Boccadoro: Janssen and GSK: Membership on an entity's Board of Directors or advisory committees; Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie: Honoraria; Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma: Research Funding. Scheid: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy; Abbvie: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Dimopoulos: Janssen: Honoraria; BMS: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Beigene: Honoraria. Weisel: Oncopeptides: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy; Novartis: Honoraria; Pfizer: Honoraria. Cavo: Adaptive Biotechnologies: Consultancy, Honoraria; Novartis: Honoraria; GlaxoSmithKline: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Accommodations, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol-Myers Squib: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Sonneveld: SkylineDx: Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding; Celgene/BMS: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding. Goldschmidt: Mundipharma: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Johns Hopkins University: Other: Grant; Molecular Partners: Research Funding; MSD: Research Funding; GSK: Honoraria; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Adaptive Biotechnology: Consultancy; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Novartis: Honoraria, Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Takeda: Consultancy, Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
32. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Bertsch, Uta, Besemer, Britta, Haenel, Mathias, Miah, Kaya, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor Wolfgang, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Kunz, Christina, Neubauer, Andreas, Scheid, Christof, Schroers, Roland, Metzler, Ivana v., Schieferdecker, Aneta, Thomalla, Joerg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glaetzer, Andrea, Weisel, Katja, Raab, Marc-Steffen, and Salwender, Hans
- Abstract
Goldschmidt: Incyte: Research Funding; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; GSK: Honoraria; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Johns Hopkins University: Other: Grant; Molecular Partners: Research Funding; MSD: Research Funding; Mundipharma: Research Funding; Novartis: Honoraria, Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Takeda: Consultancy, Research Funding; Adaptive Biotechnology: Consultancy; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding. Mai: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Glaxo Smith Kline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Celgene / BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding. Besemer: GSK: Honoraria; Janssen: Honoraria; Takeda: Honoraria. Haenel: Jazz: Consultancy, Honoraria; GSK: Consultancy; Bayer Vital: Honoraria; Takeda: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy; Celgene: Consultancy, Honoraria. Fenk: Janssen: Honoraria; Amgen: Honoraria; GSK: Honoraria; Takeda: Honoraria; BMS/Celgene: Honoraria. Munder: Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Abbvie: Consultancy; Takeda: Consultancy, Honoraria; Amgen: Honoraria; Sanofi: Consultancy; GSK: Consultancy; Incyte: Research Funding. Dürig: Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Hose: LamKap Bio: Consultancy, Current Employment; BMS: Research Funding. Scheid: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Schroers: BMS/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Takeda: Honoraria. Metzler: GSK: Consultancy; Amgen: Consultancy; Janssen: Consultancy; AstraZeneca: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy; BMS: Consultancy; Takeda: Consultancy. Schieferdecker: Sebia: Consultancy. Mahlberg: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria; BMS: Honoraria; GSK: Honoraria. Graeven: Amgen: Honoraria; Sanofi Aventis: Honoraria; Celgene: Honoraria, Research Funding; Johnson & Johnson: Honoraria; Astra Zeneca: Honoraria; MSD: Consultancy; Boehringer Ingelheim: Honoraria; BMS: Honoraria; Fujifilm: Honoraria; Roche: Research Funding; Gilead: Research Funding; Ipsen Bioscience: Research Funding; MacroGenics: Research Funding. Martens: Celgene: Consultancy; Sanofi-Aventis: Consultancy. Weisel: Adaptive Biotechnologies: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy; Novartis: Honoraria; Pfizer: Honoraria. Raab: Roche: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria; Janssen: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees. Salwender: Takeda: Honoraria; Sanofi: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; GlaxoSmithKline: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Oncopeptides: Honoraria; Chugai: Honoraria; Amgen: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; AbbVie: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Janssen-Cilag: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Bristol-Myers Squibb/Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Pfizer: Honoraria.Lenalidomide and ELotuzumab in first line therapy prior to autologous stem cell transplantation, Elotuzumab in maintenance after autologous transplantation.
- Published
- 2021
- Full Text
- View/download PDF
33. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Nievergall, Eva, Fenk, Roland, Bertsch, Uta, Tichy, Diana, Besemer, Britta, Dürig, Jan, Schroers, Roland, Metzler, Ivana v., Haenel, Mathias, Mann, Christoph, Asemissen, Anne-Marie, Heilmeier, Bernhard, Huhn, Stefanie, Kriegsmann, Katharina, Weinhold, Niels, Luntz, Steffen P., Holderried, Tobias A. W., Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Mueller, Martin, Khandanpour, Cyrus, Knauf, Wolfgang, Munder, Markus, Geer, Thomas, Riesenberg, Hendrik, Thomalla, Joerg, Hoffmann, Martin, Raab, Marc-Steffen, Salwender, Hans, and Weisel, Katja
- Abstract
Goldschmidt: Takeda: Consultancy, Research Funding; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Adaptive Biotechnology: Consultancy; Incyte: Research Funding; GSK: Honoraria; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Johns Hopkins University: Other: Grant; Molecular Partners: Research Funding; MSD: Research Funding; Mundipharma: Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Novartis: Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding. Mai: Celgene / BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Glaxo Smith Kline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accommodations and expenses, Research Funding. Fenk: Takeda: Honoraria; GSK: Honoraria; Amgen: Honoraria; Janssen: Honoraria; BMS/Celgene: Honoraria. Besemer: Takeda: Honoraria; Janssen: Honoraria; GSK: Honoraria. Dürig: Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Schroers: BMS/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Takeda: Honoraria. Metzler: Takeda: Consultancy; BMS: Consultancy; GSK: Consultancy; Amgen: Consultancy; Janssen: Consultancy; AstraZeneca: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy. Haenel: Takeda: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; GSK: Consultancy; Bayer Vital: Honoraria; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy; Celgene: Consultancy, Honoraria. Mann: Cellgene: Consultancy. Asemissen: GSK: Honoraria; Pfizer: Honoraria; Celgene BMS: Honoraria. Heilmeier: Sanofi-Aventis Dtld. GmbH: Consultancy. Kriegsmann: Sanofi: Honoraria. Weinhold: Sanofi: Honoraria. Holderried: Amgen: Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Eurocept Pharmaceuticals: Other: Travel support; MSD: Speakers Bureau; Gilead Sciences: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Other: Travel support; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Other: Travel support; Therakos: Other: Travel support; Daiichi Sankyo: Other: travel support; Medac: Other: Travel support; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Trautmann-Grill: Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria. Gezer: Amgen: Consultancy, Other: Invited Speaker; Takeda: Consultancy, Other: Invited Speaker; BMS: Consultancy, Other: Invited Speaker; Celgene: Consultancy, Other: Invited Speaker. Khandanpour: GSK: Honoraria; Takeda: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria, Research Funding; Pfizer: Honoraria; Sanofi: Honoraria, Research Funding; BMS/Celgene: Honoraria. Knauf: Amgen: Honoraria; Abbvie: Honoraria; Beigene: Consultancy, Honoraria; BMS: Honoraria; Celgene: Honoraria; Janssen: Consultancy, Honoraria; Sanofi: Honoraria; AstraZeneca: Consultancy, Honoraria. Munder: GSK: Consultancy; Amgen: Honoraria; Sanofi: Consultancy; Takeda: Consultancy, Honoraria; Abbvie: Consultancy; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Incyte: Research Funding. Hoffmann: Sanofi-Aventis: Consultancy. Raab: Roche: Consultancy; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria; Janssen: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Salwender: GlaxoSmithKline: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Sanofi: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Chugai: Honoraria; Oncopeptides: Honoraria; Takeda: Honoraria; Amgen: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; AbbVie: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Janssen-Cilag: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Bristol-Myers Squibb/Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Pfizer: Honoraria. Weisel: Adaptive Biotechnologies: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy; Novartis: Honoraria; Pfizer: Honoraria.Isatuximab prior to ASCT in NDMM
- Published
- 2021
- Full Text
- View/download PDF
34. Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma
- Author
-
John, Lukas, Miah, Kaya, Benner, Axel, Mai, Elias K, Kriegsmann, Katharina, Hundemer, Michael, Mueller-Tidow, Carsten, Jordan, Karin, Goldschmidt, Hartmut, Raab, Marc S., and Giesen, Nicola
- Abstract
Introduction:
- Published
- 2020
- Full Text
- View/download PDF
35. Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
- Author
-
Scheid, Christof, Lokhorst, Henk, Blau, Igor W, Van Der Holt, Bronno, Bertsch, Uta, Zweegman, Sonja, Weisel, Katja, Vellenga, Edo, Kersten, Marie José, Croockewit, Sandra, Mai, Elias K, Raymakers, Reinier, Hose, Dirk, Jauch, Anna, Hillengass, Jens, Stevens-Kroef, Marian, Raab, Marc S, Neben, Kai, Stilgenbauer, Stephan, Broyl, Annemiek, Lindemann, Hans-Walter, Bos, Gerard, Brossart, Peter, van Marwijk Kooij, Marinus, Ypma, Paula F, Dührsen, Ulrich, Schaafsma, Ron, Hielscher, Thomas, Salwender, Hans, Goldschmidt, Hartmut, and Sonneveld, Pieter
- Abstract
Scheid: Bristol Myers Squibb: Honoraria; Celgene: Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Bertsch:Celgene: Other: travel support; Sanofi: Other: travel support. Zweegman:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding. Weisel:Celgene: Consultancy, Honoraria, Research Funding; Juno: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Research Funding; GSK: Honoraria; Adaptive Biotech: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria. Kersten:Gilead: Honoraria; Kite Pharma: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Novartis: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding; Mundipharma: Honoraria, Research Funding; Miltenyi: Honoraria; Roche: Honoraria, Research Funding; Takeda Oncology: Research Funding; Celgene: Honoraria, Research Funding. Mai:Mundipharma: Other: travel support; Takeda: Honoraria, Other: travel support, Research Funding; Janssen: Consultancy, Honoraria, Other: travel support; Celgene: Consultancy, Honoraria, Other: travel support. Hillengass:Amgen: Consultancy, Honoraria; Janssen: Honoraria. Stilgenbauer:AbbVie, AstraZeneca, Celgene, Gilead Sciences, Inc., GSK, Hoffmann La-Roche, Janssen, Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau. Broyl:Celgene, amgen, Janssen,Takeda: Honoraria. Bos:Kiadis Pharma: Other: Shareholder (of Cytosen, acquired by Kiadis); Celgene: Research Funding. Dührsen:Amgen: Consultancy, Honoraria, Research Funding; CPT: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Roche: Honoraria, Research Funding; Teva: Honoraria; Novartis: Consultancy, Honoraria; Alexion: Honoraria; Gilead: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Honoraria; Celgene: Research Funding. Salwender:Celgene: Honoraria, Other: Travel or accommodations; Sanofi: Honoraria, Other: Travel or accommodations; Takeda: Honoraria, Other: Travel or accommodations; Bristol-Myers Squibb: Honoraria, Other: Travel or accommodations; AbbVie: Honoraria; Amgen: Honoraria, Other: Travel or accommodations; Janssen Cilag: Honoraria, Other: Travel or accommodations. Goldschmidt:Adaptive Biotechnology: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Molecular Partners: Research Funding; Dietmar-Hopp-Stiftung: Research Funding; Mundipharma: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; John-Hopkins University: Research Funding; Amgen: Consultancy, Research Funding; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Chugai: Honoraria, Research Funding; John-Hopkins University: Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; MSD: Research Funding; Janssen: Consultancy, Research Funding. Sonneveld:Amgen: Honoraria, Research Funding; BMS: Honoraria; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Karyopharm: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; SkylineDx: Research Funding.bortezomib maintenance thalidomide maintenance
- Published
- 2019
- Full Text
- View/download PDF
36. Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
- Author
-
Scheid, Christof, Lokhorst, Henk, Blau, Igor W, Van Der Holt, Bronno, Bertsch, Uta, Zweegman, Sonja, Weisel, Katja, Vellenga, Edo, Kersten, Marie José, Croockewit, Sandra, Mai, Elias K, Raymakers, Reinier, Hose, Dirk, Jauch, Anna, Hillengass, Jens, Stevens-Kroef, Marian, Raab, Marc S, Neben, Kai, Stilgenbauer, Stephan, Broyl, Annemiek, Lindemann, Hans-Walter, Bos, Gerard, Brossart, Peter, van Marwijk Kooij, Marinus, Ypma, Paula F, Dührsen, Ulrich, Schaafsma, Ron, Hielscher, Thomas, Salwender, Hans, Goldschmidt, Hartmut, and Sonneveld, Pieter
- Abstract
Background:
- Published
- 2019
- Full Text
- View/download PDF
37. Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial
- Author
-
Boquoi, Amelie, Giagounidis, Aristoteles, Goldschmidt, Hartmut, Heinsch, Michael, Rummel, Mathias J, Kroeger, Nicolaus, Lopez y Niedenhoff, David, Wilk, C. Matthias, Savickaite, Ingrida, Mai, Elias K, Aul, Carlo, Strapatsas, Judith, Dienst, Ariane, Kondakci, Mustafa, Haas, Rainer, Kobbe, Guido, and Fenk, Roland
- Abstract
Introduction
- Published
- 2018
- Full Text
- View/download PDF
38. Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial
- Author
-
Boquoi, Amelie, Giagounidis, Aristoteles, Goldschmidt, Hartmut, Heinsch, Michael, Rummel, Mathias J, Kroeger, Nicolaus, Lopez y Niedenhoff, David, Wilk, C. Matthias, Savickaite, Ingrida, Mai, Elias K, Aul, Carlo, Strapatsas, Judith, Dienst, Ariane, Kondakci, Mustafa, Haas, Rainer, Kobbe, Guido, and Fenk, Roland
- Abstract
Boquoi: Amgen: Honoraria, Other: Travel grant; Bristol-Myers Squibb: Honoraria; Janssen: Other: Travel grant; Celgene: Other: Travel grant. Goldschmidt:Celgene: Consultancy, Honoraria, Research Funding; Chugai: Honoraria, Research Funding; ArtTempi: Honoraria; Takeda: Consultancy, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Honoraria, Research Funding; Mundipharma: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Research Funding; Adaptive Biotechnology: Consultancy. Rummel:Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Mundipharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Eisai: Honoraria; Celgene: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Symbio: Honoraria. Kroeger:Sanofi: Honoraria; JAZZ: Honoraria; Novartis: Honoraria, Research Funding; Neovii: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Riemser: Honoraria, Research Funding. Mai:Celgene: Other: travel grant; Janssen: Honoraria, Other: Travel grant; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding; Onyx: Other: travel grant; Mundipharma: Other: travel grant. Kobbe:Amgen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Celgene: Honoraria, Other: Travel Support, Research Funding. Fenk:Amgen: Honoraria; Takeda: Honoraria; Celgene: Honoraria, Other: Travel grant, Research Funding; Bristol-Meyers Squibb: Honoraria, Other: travel grant; Janssen: Honoraria.
- Published
- 2018
- Full Text
- View/download PDF
39. A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials
- Author
-
Mai, Elias K, Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans Jürgen, Lokhorst, Henk M, Munder, Markus, van der Holt, Bronno, Gerecke, Christian, Pfreundschuh, Michael, Duhrsen, Ulrich, Brossart, Peter, Zweegman, Sonja, Neben, Kai, Hillengass, Jens, Raab, Marc-Steffen S, Hose, Dirk, Vellenga, Edo, Merz, Maximilian, Breitkreutz, Iris, Jauch, Anna, Kersten, Marie José, Martin, Hans, Lindemann, Hans-Walter, Peter, Norma, Croockewit, Sandra, Blau, Igor Wolfgang, Scheid, Christof, Weisel, Katja C., Sonneveld, Pieter, and Goldschmidt, Hartmut
- Abstract
Introduction:Early mortality is up to 10% in newly diagnosed multiple myeloma (MM) with no improvement in subsequent study generations until 2002 (Augustson et al., JCO, 2005). Recent data on the causes of early mortality in transplant-eligible (te) MM patients during induction therapy (IT) and associated risk factors are not available.
- Published
- 2017
- Full Text
- View/download PDF
40. Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial
- Author
-
Scheid, Christof, Seckinger, Anja, Dürig, Jan, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Munder, Markus, Lindemann, Hans-Walter, Huegle-Doerr, Barbara, Huhn, Stefanie, Mai, Elias K, Jauch, Anna, Rabold, Bernhard, Gerecke, Christian, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc-Steffen S, Blau, Igor Wolfgang, Haenel, Mathias, Hose, Dirk, Goldschmidt, Hartmut, and Salwender, Hans Jürgen
- Abstract
Background:Response criteria in myeloma have been developed to predict treatment outcome and to compare results from clinical trials. The current IMWG response criteria (Kumar, Lancet Oncology 2016) are based on paraprotein assessment by immunofixation and electrophoresis of serum and urine. The hevylite (HLC) assay directly quantifies the kappa and lambda fractions of IgG, IgA and IgM as well as the corresponding kappa/lambda ratios. To compare the response assessment by IMWG criteria and by HLC we applied the test to serum samples from the prospective GMMG MM5 trial in newly diagnosed myeloma patients.
- Published
- 2017
- Full Text
- View/download PDF
41. Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial
- Author
-
Goldschmidt, Hartmut, Mai, Elias K, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Munder, Markus, Lindemann, Hans-Walter, Huegle-Doerr, Barbara, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Jauch, Anna, Rabold, Bernhard, Elmaagacli, Ahmet, Gerecke, Christian, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc-Steffen S, Blau, Igor Wolfgang, Hänel, Mathias, and Salwender, Hans Jürgen
- Published
- 2017
- Full Text
- View/download PDF
42. IKZF1/3 and CRL4CRBNE3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma
- Author
-
Barrio Garcia, Santiago, Da Via', Matteo, Garitano-Trojaola, Andoni, Ruiz-Heredia, Yanira, Bittrich, Max, Shi, ChangXin, Zhu, Yuan, Lehners, Nicola, Mai, Elias K, Raab, Marc S, Sonneveld, Pieter, Martínez, Joaquín, Rosenwald, Andreas, Braggio, Esteban, Einsele, Hermann, Stewart, A. Keith, and Kortüm, K. Martin
- Abstract
Immunomodulatory drugs (IMiDs) provide the backbone for various Multiple Myeloma (MM) treatment regimens. Cereblon (CRBN) is the known key modulator of the IMiD anti-tumor effects as it is the intermediate protein within the CRL4CRBNE3 ubiquitin ligase (CRL4) complex that targets the degradation of the two transcription factors, Ikaros (IKZF1) and Aiolos (IKZF3). We hypothesize that the formation of thiscomplex (CRBN-DDB1-CUL4B-ROC1) is essential for the IMiD's action and that mutations that occur in involved genes affect its assemblage, thus induce IMiD resistance.
- Published
- 2017
- Full Text
- View/download PDF
43. Comprehensive Genomic Characterization of Refractory Multiple Myeloma Reveals a Complex Mutational and Structural Landscape Associated with Drug Resistance
- Author
-
Lehners, Nicola, Toprak, Umut H, Xu, Jing, Paramasivam, Nagarajan, Hübschmann, Daniel, Fröhlich, Martina, Hanafiah, Nur H Md, Mughal, Sadaf, Mai, Elias K, Jauch, Anna, Hillengass, Jens, Eils, Roland, Müller-Tidow, Carsten, Brors, Benedikt, Goldschmidt, Hartmut, Schlesner, Matthias, and Raab, Marc S
- Abstract
Introduction: Despite the improvement in prognosis of multiple myeloma (MM), patients refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) still experience a very poor outcome. While sequencing endeavors in recent years have comprehensively described the genetic composition of newly diagnosed and relapsed MM, the mutational landscape of refractory MM (rMM) remains elusive.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.